Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 15 July 2022, including: a setback for a COVID candidate; Chinese biotechs move into mRNA; Sanofi builds hemophilia presence; Orion Corporation’s deal for its novel prostate cancer candidate; and Roche Holding AG’s evolving approach to platform deals.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet" - Scrip, 13 Jul, 2022.)
(Also see "BeiGene Latest Chinese Biotech To Double Down On mRNA For Cancer" - Scrip, 11 Jul, 2022.)
(Also see "Sanofi Has One Hemophilia Winner On It Hands – But Fitusiran’s Fate Remains Unclear" - Scrip, 11 Jul, 2022.)
(Also see "Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal" - Scrip, 13 Jul, 2022.)
(Also see "Roche Partnering Finds Upfront Fee Relief In Current Market" - Scrip, 8 Jul, 2022.)